SAFE Act

Bill Number

H.R. 830

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Crime and Law Enforcement

Status

Introduced

Latest Action

2025-01-31: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2026-07-11T06:08:10Z

AI-Generated Summary

Summary of H.R. 830: Save Americans from the Fentanyl Emergency Act (SAFE Act)

Purpose

The legislation aims to address the fentanyl overdose crisis by permanently classifying a broad category of fentanyl-related substances (chemical variants structurally similar to fentanyl) as Schedule I controlled substances under the Controlled Substances Act (CSA). It seeks to close loopholes that allow new fentanyl variants to evade scheduling, while providing mechanisms for scientific review to remove or reschedule low-risk substances, easing research barriers, and adjusting penalties to focus enforcement on the most dangerous forms of fentanyl.

Key Provisions

• Class Scheduling of Fentanyl-Related Substances (Sec. 2): Adds a new subsection (e) to Schedule I of the CSA, automatically classifying any substance structurally related to fentanyl (via specified chemical modifications, such as substitutions on the phenethyl group or piperidine ring) as a Schedule I drug, unless exempted or separately listed. The Attorney General must publish a list of such substances in the Federal Register within 60 days of identification, but absence from the list does not exempt them. These substances are exempt from quantity-based mandatory minimum prison sentences under certain CSA penalty provisions.

• Adjusted Penalties for Domestic Offenses (Sec. 3): Modifies CSA penalties for manufacturing, distributing, or possessing fentanyl or its analogues:
• Increases thresholds for mandatory minimums (e.g., 400 grams for 10-year minimum for fentanyl; 100 grams for analogues).
• Treats fentanyl-related substances under general Schedule I penalties (5-year minimum for smaller amounts), excluding them from the higher fentanyl-specific thresholds.

• Adjusted Penalties for Import/Export Offenses (Sec. 4): Similar changes to the Controlled Substances Import and Export Act, aligning thresholds (e.g., 400 grams/100 grams for fentanyl/analogues) and applying general Schedule I penalties to fentanyl-related substances.

• Removal or Rescheduling Process (Sec. 5): Allows the Secretary of Health and Human Services (HHS) to evaluate fentanyl-related substances for removal from Schedule I or rescheduling to Schedule III if abuse potential is low (less than Schedule V or Schedules I/II drugs, respectively). Evaluations consider factors like actual abuse, pharmacological effects (via studies on opioid receptor activity), and scientific evidence. The HHS determination binds the Attorney General, who must act within 90 days. Exceptions apply for international treaty obligations. Petitions for removal are allowed, and the Attorney General must notify HHS of new identifications.

• Relief for Past Convictions (Sec. 6): Courts may vacate or reduce sentences for past offenses involving rescheduled or removed fentanyl-related substances, considering sentencing factors under 18 U.S.C. § 3553(a). This applies to both domestic and import/export cases; defendants need not be present for hearings. Reductions are discretionary.

• Research Registration Facilitations (Sec. 7): Streamlines DEA registration for Schedule I research, especially for fentanyl-related substances:
• Allows expedited notices or applications for certain federally funded or investigational research (e.g., under FDA or HHS grants).
• Permits multiple researchers in the same institution or sites within the same city/county to share one registration, with notifications to the DEA.
• Waives new inspections for adding similar-scheduled substances.
• Allows ongoing research on newly scheduled substances for up to 90 days while applying for registration.
• Treats small-scale manufacturing (e.g., creating extracts or dosage forms for research) as part of research registration, excluding marijuana growth.
• Requires public transparency on any special research processes.

• Rulemaking and Reporting (Secs. 8-9): The Attorney General must issue implementing rules within one year (as interim final rules). The Government Accountability Office (GAO) must report to Congress within four years on implementation, including impacts on research, trafficking, sentencing, and class scheduling efficacy, consulting stakeholders like HHS, DOJ, and law enforcement.

Significant Changes to Existing Law

• Class-Wide Scheduling: Shifts from individual scheduling of fentanyl analogues (which can take months) to automatic inclusion in a new Schedule I category based on structure, enabling faster control of emerging variants without repeated DEA actions.
• Penalty Differentiation: Raises quantity thresholds for fentanyl and non-class analogues to trigger mandatory minimums (e.g., from 1 gram to 40 grams for 5-year minimums), while fentanyl-related substances face standard Schedule I penalties without quantity minimums, potentially leading to more proportionate sentencing.
• Scientific-Driven Rescheduling: Introduces binding HHS authority for removals/rescheduling based on abuse potential evidence, overriding prior DEA-led processes; includes specific study requirements (e.g., receptor binding assays) for evaluations.
• Research Reforms: Replaces cumbersome, site-by-site registrations with notifications and shared registrations, reducing administrative burdens; allows continuation of research during newly scheduled substances' transitions, a new provision.
• Sentence Relief Mechanism: Adds discretionary post-conviction relief for rescheduled substances, not previously available in the CSA for scheduling changes.

Potential Impacts

• Government Agencies: Enhances DEA and HHS efficiency in scheduling and research oversight; requires interagency coordination (e.g., HHS evaluations, GAO reporting). May increase workload for courts in handling sentence reductions but streamlines research approvals, potentially boosting federally funded studies on fentanyl alternatives or treatments.
• Citizens: Could reduce overdose deaths by quicker control of new fentanyl variants, aiding public health. Defendants with past convictions may seek lighter sentences, promoting fairness, but ongoing traffickers face adjusted (potentially harsher for pure fentanyl) penalties. Researchers gain easier access to Schedule I substances, fostering innovation in pain management or addiction treatments.
• International Relations: Ensures U.S. compliance with drug control treaties by exempting obligated substances from rescheduling; may influence global efforts against fentanyl trafficking, particularly from sources like China or Mexico, by standardizing controls.

Main Stakeholders Affected

• Law Enforcement and Justice System: DEA, DOJ, federal prosecutors, and courts benefit from faster scheduling but must adapt to differentiated penalties and sentence reviews.
• Public Health and Research Community: HHS, FDA, academic researchers, and institutions (e.g., universities, VA hospitals) gain from streamlined registrations, enabling more studies on fentanyl safety or alternatives.
• Individuals and Communities: People convicted of fentanyl-related crimes (potential for reduced sentences); overdose victims and families (improved crisis response); substance users and addicts (possible access to rescheduled, less restricted substances if deemed low-risk).
• Industry and Regulators: Pharmaceutical manufacturers and distributors face fewer barriers for research-scale production; international partners in drug control (e.g., via UN conventions).

Notable Legal, Constitutional, or Political Implications

• Legal: Introduces a novel "class scheduling" approach, which may face challenges if deemed overly broad (potentially violating due process by presuming control without individual review), but includes safeguards like HHS evaluations and petition rights. Penalty adjustments could reduce disparities in sentencing (e.g., avoiding mandatory minimums for minor fentanyl-related offenses), aligning with calls for criminal justice reform. Research provisions enhance First Amendment protections for scientific inquiry by reducing bureaucratic hurdles.
• Constitutional: Respects treaty obligations under Article VI (supremacy clause), preventing conflicts with international law. Discretionary sentence relief avoids ex post facto issues by applying prospectively to rescheduling events.
• Political: Reflects bipartisan urgency on the opioid crisis (introduced by Republicans), balancing strict enforcement with science-based flexibility and research support. The GAO report ensures accountability, potentially informing future drug policy debates on analogue laws versus innovation. No direct funding or appropriations, relying on existing agency resources.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Pappas, Chris [D-NH-1]

Cosponsors (17)

Rep. Salazar, Maria Elvira [R-FL-27], Rep. Newhouse, Dan [R-WA-4], Rep. Crow, Jason [D-CO-6], Rep. Houlahan, Chrissy [D-PA-6], Rep. Figures, Shomari [D-AL-2], Rep. Craig, Angie [D-MN-2], Rep. McClellan, Jennifer L. [D-VA-4], Rep. Budzinski, Nikki [D-IL-13], Rep. Olszewski, Johnny [D-MD-2], Rep. Peters, Scott H. [D-CA-50], Rep. Connolly, Gerald E. [D-VA-11], Rep. Cisneros, Gilbert Ray, Jr. [D-CA-31], Rep. Davids, Sharice [D-KS-3], Rep. Ruiz, Raul [D-CA-25], Rep. Bera, Ami [D-CA-6], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Magaziner, Seth [D-RI-2]

Recent Actions

• 2025-01-31: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-01-31: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-01-31: Introduced in House
• 2025-01-31: Introduced in House

Bill Versions

• Save Americans from the Fentanyl Emergency Act — issued 2025-01-31 — PDF (32 pages)